This Antibody was verified by Knockdown to ensure that the antibody binds to the antigen stated. View Details
Description: This GMPR9 monoclonal antibody reacts with human and mouse Sox9, a member of the Sry HMG-box (Sox) gene family of transcription factors. Like Sry, Sox9 contains a high mobility group (HMG-box) DNA-binding domain. The Sox9 DNA-binding domain recognizes the sequence AGAACAATGG, and when bound to co-factors, functions to bend the DNA. This structural change is thought to be important for chromatin remodeling and the initiation of more broad transcriptional regulation of multiple genes. Sox9 is expressed in multiple tissue types during development and its activation of downstream targets is determined by interaction with tissue-specific co-factors. During development, Sox9 expression is important for cartilage formation (mesenchymal to chondrocyte), sex determination (testes formation), neural crest formation and retinal development. Sox9 plays a role in the differentiation of multiple cell types including glial, hair, cardiac, melanocytes, pancreatic, prostate, and intestinal epithelium. Sox9 regulates expression of the following family member genes sox5, sox6, and sox10, in addition to collagen type 2 alpha, collagen 9A1, CEACAM1, and snail2. Sox9 dysregulation is involved in craniofacial defects, cleft palate, sex reversal, and some types of cancer (melanoma, lung adenocarcinoma, and breast cancer). Sox9 has also been shown to be expressed in adult stem cells in the liver, pancreas and intestine.
Applications Reported: This GMPR9 antibody has been reported for use in western blotting, immunohistochemical staining of formalin-fixed paraffin embedded tissue sections, microscopy, and immunocytochemistry.
Applications Tested: This GMPR9 antibody has been tested by immunohistochemistry of formalin fixed paraffin embedded human tissue using high or low pH antigen retrieval and can be used at less than or equal to 1 µg/mL. This GMPR9 antibody has been tested by immunocytochemistry of fixed and permeabilized human cells and can be used at less than or equal to 1 µg/mL. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.
Purity: Greater than 90%, as determined by SDS-PAGE.
Aggregation: Less than 10%, as determined by HPLC.
Filtration: 0.2 µm post-manufacturing filtered.
SOX9 has a role in sex determination and differentiation of Sertoli cells. It is involved in chondrogenesis and regulates the expression of other genes involved in chondrogenesis by acting as a transcription factor for these genes. Translocation of this gene can cause campomelic dysplasia. SOX9 is involved in the formation of testes from the indifferent fetal gonads. It is a major molecular component of the neuron-glia switch in developing spinal cord. During normal development, SOX9 allows the prostate epithelium to outgrow into the mesenchyme and then provides basal cell support for development and maintenance of the luminal epithelium. These functions of SOX9 are subverted in prostate cancer to support tumor growth and invasion. SOX9 may direct the formation of neural crest precursors and the development of a range of neural crest derivative. It has a transcriptional regulation in melanin production in cells. Northern blot analysis shows its expression on adult testis, adult heart, and fetal brain.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: SOX 9; SRY (sex determining region Y)-box 9; SRY (sex determining region Y)-box 9 (campomelic dysplasia, autosomal sex-reversal); SRY (sex determining region Y)-box9; SRY (sex-determining region Y)-box 9 protein; SRY box 9; SRY-Box 9 ; SRY-box containing gene 9; SRY-related HMG-box, gene 9; Transcription factor SOX-9
Gene Aliases: 2010306G03Rik; AV220920; CMD1; CMPD1; mKIAA4243; Sox-9; SOX9; SRA1; SRXX2; SRXY10